Enlivex Therapeutics (ENLV) said Wednesday it received authorization from the Israeli Ministry of Health to start a phase 1 clinical trial of Allocetra after injection into the temporomandibular joint in osteoarthritis patients.
The company intends to evaluate the frequency and severity of adverse events, including serious adverse events, as the primary safety endpoint of the trial, which will enroll six participants, it added.
Enlivex said that efficacy endpoints will focus on changes from baseline in temporomandibular joint pain, joint functionality, and other disease parameters for up to 12 months following the injection of Allocetra.
Shares of Enlivex Therapeutics were down 1.6% in recent trading.
Price: 1.23, Change: -0.02, Percent Change: -1.60
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。